US 11,891,372 B2
Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Christopher Scott Seadeek, West Lafayette, IN (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by PFIZER INC., New York, NY (US)
Filed on Oct. 6, 2021, as Appl. No. 17/494,923.
Application 17/494,923 is a continuation of application No. 16/521,742, filed on Jul. 25, 2019, granted, now 11,168,066.
Application 16/521,742 is a continuation of application No. 15/567,433, granted, now 10,414,748, issued on Sep. 17, 2019, previously published as PCT/IB2016/052107, filed on Apr. 13, 2016.
Claims priority of provisional application 62/152,108, filed on Apr. 24, 2015.
Prior Publication US 2022/0024893 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/04 (2006.01); A61K 31/4439 (2006.01)
CPC C07D 401/04 (2013.01) [A61K 31/4439 (2013.01); C07B 2200/13 (2013.01)] 40 Claims
 
1. A method of treating a hematologic malignancy in a mammal having said hematologic malignancy, comprising administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of a crystalline form of 1-(2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, having the structure:

OG Complex Work Unit Chemistry
and having a powder X-ray diffraction pattern comprising peaks at 2θ values of: 11.6, 12.1 and 19.6°2θ±0.2°2θ, and a pharmaceutically acceptable excipient.